Emcure Pharmaceuticals Limited IPO: Should You Subscribe? Check What Brokerages Are Saying

Brokerage houses have pegged the company's market capitalisation to over Rs 19,000 crore post-issue.

New Delhi: Bain Capital-backed Emcure Pharma launched its Initial Public Offering (IPO) on July 3.The initial share sale will conclude on July 5, according to the Red Herring Prospectus (RHP).

At a price band of Rs 960 to Rs 1,008 per share, the IPO comprises fresh issuance of equity shares worth Rs 800 crore and an Offer of Sale (OFS) of 1.14 crore equity shares by promoters and existing shareholders.

Emcure Pharmaceuticals Limited IPO: Should You Subscribe? Here's What Brokerages Are Saying

Emcure Pharmaceuticals IPO - Brokerage Reports
Sr. No.	Brokerage House	Recommendation
1	Anand Rathi	Subscribe for long term
2	BP Wealth	Subscribe
3	Canara Bank Securities	Subscribe for long term
4	Deven Choksey	Subscribe
5	Geojit	Subscribe
6	Hensex Securities	Subscribe for long term
7	SBI Securities	Subscribe for long term
8	Marwadi Financial	Subscribe
9	Mastertrust	Subscribe for long term
10	Mehta Equities	Subscribe for long term
11	Nirmal Bang	Subscribe
12	Reliance Securities	Subscribe
13	Sushil Finance	Subscribe for medium-long term
14	Stoxbox	Subscribe
15	Swastika Invesmart	Subscribe for long term
16	Ventura Securities	Subscribe

Emcure Pharmaceuticals garnered Rs 583 crore from anchor investors on July 2, a day before its IPO Opening. Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India are the book-running lead managers to the issue. The equity shares of the company are expected to list on the BSE and the NSE on July 10.